Hidradenitis Suppurativa: Opportunity Analysis and Forecasts to 2028
- Pages: 83
- Published: July 2019
- Report Code: GDHC098POA
Hidradenitis Suppurativa (HS) is a chronic, inflammatory, debilitating skin disease that is characterized by the recurrent development of painful nodules and abscesses that rupture. This leads to the formation of sinus tracts and scarring on the skin. The exact cause of HS is unknown, and it is hypothesized that genetic and environmental factors are the key causes of the disease Environmental factors such as smoking, obesity, and being overweight are considered to be trigger factors in HS development. Additionally, genetic factors are also believed to play a key role in the development of HS. DNA studies have revealed that approximately one-third of patients with HS have a family history of HS. Studies have also shown that there are inheritance patterns within families who are affected by HS.
GlobalData estimates the 2018 sales for the HS market at approximately $898 million across the 7MM, encompassing the US, the five major European Union countries (5EU: France, Germany, Italy, Spain, and UK) and Japan. Over the course of the 10-year forecast period, the HS market will grow at a Compound Annual Growth Rate (CAGR) of 7.2% across the 7MM. Each of the 7MM are anticipated to grow significantly, recording CAGRs of 9.9%, 1.2% and -0.5% across the US, 5EU and Japan, respectively. At the end of 2028, the US will account for 79.1% of sales across the 7MM, while the 5EU and Japan will account for around 20.9% of sales. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of HS in the region, as well as the anticipated high annual cost of therapy (ACOT) of biologics in the US market.
Key Questions Answered
How will the HS market landscape in the 7MM (US, France, Germany, Italy, Spain, UK and Japan) change from 2018–2028?
What are the most promising late-stage pipeline drugs in HS?
How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
What are the greatest unmet needs in HS? Will the pipeline drugs fulfil these needs of the market?
What are the largest opportunities in the HS landscape?
Overview of HS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
Topline HS market revenue from 2018–2028. ACOT and major pipeline product sales in this forecast period are included.
Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HS therapeutics sales in the 7MM.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
Analysis of the current and future market competition in the global HS therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global HS therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HS therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Hidradenitis Suppurativa: Executive Summary
2.1 New Entrants Will Drive Modest Growth Across the 7MM from 2018 to 2028
2.2 Launch of Pipeline Therapies Will Lead to Change in the HS Landscape
2.3 High Unmet Needs Exists in the HS Market, Especially for a Highly Efficacious Treatment
2.4 Pipeline Agents Will Offer Incremental Improvements Over Current Therapies
2.5 What Do Physicians Think?
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for HS (2018–2028)
5.5.1 Diagnosed Active Prevalent Cases of HS
5.5.2 Age-Specific Diagnosed Active Prevalent Cases of HS
5.5.3 Sex-Specific Diagnosed Active Prevalent Cases of HS
5.5.4 Diagnosed Active Prevalent Case of HS by Severity
5.5.5 Diagnosed Active Prevalent Cases of HS with IBD
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Current Treatment Options
7 Unmet Needs and Opportunity Assessment
7.2 Lack of Efficacious Treatment
7.3 Early Diagnosis of HS
7.4 Lack of Treatment Options for Fibrosis
7.5 Lack of Holistic Management of HS
8 R&D Strategies
8.1.1 Biological Therapies
8.1.2 Oral Therapies
8.2 Clinical Trial Design
8.2.1 Current Clinical Trial Design
8.2.2 Limitations and Future Outlook
9 Pipeline Assessment
9.2 Innovative Early-Stage Approaches
10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
11.3.1 Forecasting Methodology
11.3.2 Diagnosed Patients
11.3.3 Percent Drug-Treated Patients
11.3.4 Drugs Included in Each Therapeutic Class
11.3.5 Launch and Patent Expiry Dates
11.3.6 General Pricing Assumptions
11.3.7 Individual Drug Assumptions
11.3.8 Generic Erosion
11.3.9 Pricing of Pipeline Agents
11.4 Primary Research – KOLs Interviewed for This Report
11.5 Primary Research – Prescriber Survey
11.6 About the Authors
11.6.2 Therapy Area Director
11.6.3 Managing Epidemiologist
11.6.4 Global Director of Therapy Analysis and Epidemiology
11.6.5 Global Head and EVP of Healthcare Operations and Strategy
11.7 About GlobalData
11.8 Contact Us
List of Tables
Table 1: Hidradenitis Suppurativa: Key Metrics in the 7MM
Table 2: Classification of Hidradenitis Suppurativa
Table 3: Risk Factors and Comorbidities for Hidradenitis Suppurativa
Table 4: Treatment Guidelines for HS
Table 5: Leading Treatments for Hidradenitis Suppurativa, 2019
Table 6: Clinical Trial Design for HS Pipeline Agents in Late-Stage Development, 2018
Table 7: Innovative Early-Stage Approaches for Hidradenitis Suppurativa, 2018
Table 8: Clinical Benchmark of Key Pipeline Drugs – HS, 2018
Table 9: Commercial Benchmark of Key Pipeline Drugs – Hidradenitis Suppurativa, 2018
Table 10: Key Events Impacting Sales for HS, 2018–2028
Table 11: Hidradenitis Suppurativa Market – Global Drivers and Barriers, 2018–2028.
Table 12: Key Historical and Projected Launch Dates for HS
Table 13: Key Historical and Projected Patent Expiry Dates for HS
Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for HS in 2018 and 2028
Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Humira
Figure 3: Pathophysiology of Hidradenitis Suppurativa
Figure 4: Diagnosed Active Prevalence of HS, 7MM, Men and Women, Ages ≥18 Years, 2018, (%)
Figure 5: Sources Used and Not Used for Diagnosed Active Prevalence of HS
Figure 6: Sources Used for Severity of HS
Figure 7: Sources Used for Digestive Comorbidities of HS
Figure 8: Diagnosed Active Prevalent Cases of HS, 7MM, Men and Women, Ages ≥18 Years, 2018, N
Figure 9: Age-Specific Diagnosed Active Prevalent Cases of HS, 7MM, Men and Women, Ages ≥18 Years, 2018, N
Figure 10: Sex-Specific Diagnosed Active Prevalent Cases of HS, 7MM, Men, Women, Ages ≥18 Years, 2018, N
Figure 11: Diagnosed Active Prevalent Cases of HS by Severity, 7MM, Men and Women, Ages ≥18 Years, 2018, N
Figure 12: Diagnosed Active Prevalent Cases of HS with IBD, 7MM, Men and Women, Ages ≥18 Years, 2018, N
Figure 13: Treatment Algorithm for HS
Figure 14: Unmet Needs and Opportunities in Hidradenitis Suppurativa
Figure 15: Overview of the Development Pipeline in HS
Figure 16: 7MM, Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to be Launched for HS During the Forecast Period
Figure 17: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Humira
Figure 18: Global (7MM) Sales Forecast, by Country, for HS in 2018 and 2028
Figure 19: Global Sales Forecast by Class for HS in 2018 and 2028
Figure 20: Sales Forecast by Class for HS in the US in 2018 and 2028
Figure 21: Sales Forecast by Class for HS in the 5EU in 2018 and 2028
Figure 22: Sales Forecast by Class for HS in Japan in 2018 and 2028